STAT+: AI scribe clinical trial results are here. What do they actually reveal?
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
You\u2019re reading the web edition of STAT\u2019s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine.\u00a0Sign up to get it<\/a>\u00a0delivered in your inbox every Wednesday.<\/em>\u00a0<\/p>\n Two things of note:<\/p>\n Remember when I asked if we were adopting ambient AI scribes based on vibes<\/a>? Well, we\u2019ve taken one step towards un-vibing the AI scribe space. Last week, NEJM AI published the first randomized, controlled trials for AI scribes.<\/p>\n I won\u2019t rehash the details here; you can read all about it<\/a> in my story with Mario Aguilar that\u2019s out this morning. But there are two points I\u2019ll emphasize here.<\/p>\n We\u2019ve run so many studies on the effect of AI scribes on clinicians and these new RCTs just tell us what we\u2019ve known all along: Doctors like the tech, and it saves a little time, but not a lot.\u00a0<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n\n
The ambient AI scribe clinical trials are here\u00a0<\/h2>\n
Why do we need RCTs anyway?<\/h3>\n